Atlas Arteria Announces Issuance of 2.24 Million Shares Following Deemed Change of Control Event

Atlas Arteria’s Infrastructure Portfolio and Market Standing

Atlas Arteria Limited is a prominent ASX-listed infrastructure investment firm with a diversified asset portfolio and operations. The company holds a significant footprint in the Australian market through various infrastructure investments. Operating under ABN 56 141 075 201 and internationally via Atlas Arteria International Limited (ARBN 141 528 841), it is a key player in the infrastructure sector on the ASX.

The company’s capital structure and share issuance practices reflect its maturity as a listed entity that manages employee remuneration through performance-based equity schemes. Atlas Arteria’s sector typically involves long-term asset holdings, toll-based revenue streams, and exposure to both domestic and international markets. The use of employee incentive schemes highlights the company’s commitment to aligning management and employee interests with shareholder value creation over extended periods.

Impact of the Deemed Change of Control Event on Incentive Plans

The issuance of 2,235,744 shares on 22 July 2026 was triggered by an Incentive Deemed Change of Control event, as outlined in Atlas Arteria’s Target’s Statement dated 26 May 2026. Such events typically activate provisions within employee incentive plans that accelerate vesting of previously unvested performance rights. Consequently, the company’s long-term incentive plan (LTIP), executive equity incentive plan (EEIP), and other performance rights vested, converting into fully paid ordinary shares eligible for ASX quotation.

This Deemed Change of Control mechanism safeguards participants during significant corporate restructuring or ownership changes by ensuring immediate vesting. This led to approximately 2.24 million new ordinary shares requiring ASX quotation to enable trading. The referenced Target’s Statement provides comprehensive details on the event’s definition and application.

Share Allocations to Key Management Personnel

The update reveals that two key management personnel were major beneficiaries of the share issuance following the Incentive Deemed Change of Control event. Hugh Wehby received 1,205,400 fully paid ordinary shares, and Vincent Portal-Barrault was allocated 523,446 shares, both held via Solium Nominees (Australia) Pty Ltd. These allocations represent the largest portions of the total 2,235,744 shares issued.

Solium Nominees (Australia) Pty Ltd serves as the registered holder, a common practice in Australian corporate administration for managing employee share schemes while preserving beneficial ownership. The substantial allocations to these senior executives reflect their roles and participation in higher-tier long-term incentive arrangements. Remaining shares were distributed among other eligible employees under the deemed change of control provisions.

Valuation and Consideration of the Share Issuance

No cash consideration was paid for the 2,235,744 shares issued on 22 July 2026, as these shares were granted under employee incentive schemes in exchange for prior service and performance rather than monetary payment. The estimated value per share was AUD 5.10, representing the deemed market value used for accounting and regulatory disclosures.

This valuation is important for understanding the economic substance of the issuance, tax implications, and establishing the base cost for capital gains calculations. The nil cash consideration is typical for performance rights vesting, where shares are issued as fulfillment of previously granted rights rather than new cash investments.

Quotation and Capital Structure After Issuance

Following the quotation of these shares, Atlas Arteria’s total quoted securities in the FPO STAP US PROHIBITED EXCLUDING QIB/QP class will total 1,453,493,469 shares. This class constitutes the company’s primary quoted securities on the ASX, representing the ordinary shares available for trading.

Additionally, 733,226 unquoted performance rights will remain outstanding, representing future equity incentives yet to vest or convert. The coexistence of significant quoted share capital alongside unquoted performance rights underscores the company’s ongoing use of equity-based remuneration as part of its employee engagement strategy. Newly quoted shares will rank equally with existing shares, providing identical economic and voting rights from their issue date.

Employee Incentive Scheme Governance and Shareholder Approval

Atlas Arteria’s employee incentive schemes are detailed in publicly available documents, including the 2026 Notice of Meeting and the 2025 Annual Report with the Remuneration Report. These filings, lodged with the ASX, disclose the operation of the incentive schemes, including vesting conditions, performance metrics, and change of control provisions that triggered this share issuance.

The 2026 Notice of Meeting presented these schemes for shareholder approval or ratification, ensuring transparency and governance. The share issuance utilized the company’s 15 percent placement capacity under ASX Listing Rule 7.1, which permits issuance of up to 15 percent of issued capital within 12 months without separate shareholder approval. Since the 2,235,744 shares fell within this limit, no additional shareholder approval was necessary for this issuance.

Strategic Importance of the Incentive Deemed Change of Control Provision

The Incentive Deemed Change of Control event triggering the July 2026 share vesting indicates a significant corporate transaction or restructuring at Atlas Arteria. Such provisions protect employees and management by accelerating vesting when ownership or control changes substantially.

The Target’s Statement dated 26 May 2026 provided shareholders with details on the event’s nature, rationale, and implications for the company’s future. Accelerated vesting aligns management interests during transitions and ensures employees retain benefits earned through long-term service. The simultaneous vesting of multiple incentive schemes and issuance of approximately 2.24 million shares highlights the material impact of this comprehensive change of control event.

Issuance Timeline and Market Procedures

The shares were issued on 22 July 2026, with the ASX quotation application filed on 24 July 2026. This prompt application aligns with standard practice to enable trading liquidity for participants. The timing, approximately two months after the Target’s Statement on 26 May 2026, reflects the structured timeline for approvals and settlement typical in major corporate transactions.

Regulatory Compliance and Disclosure

Atlas Arteria’s quotation application complies with ASX Listing Rule requirements for securities issued under employee incentive schemes. Submitted as an Appendix 2A to the ASX, the update includes full disclosure of issuance details, consideration, KMP recipients, and the resulting capital structure.

References to the 2026 Notice of Meeting and 2025 Annual Report provide investors with comprehensive information on the incentive schemes and share issuance terms. The inclusion of the Target’s Statement enables tracing of the corporate event context. This layered disclosure approach meets ASX regulatory standards and best practice governance for material capital structure changes.